-
Innovation Ranking
NewInnovation Ranking – Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc (Arrowhead), formerly Arrowhead Research Corp, is a pharmaceutical company. It develops and markets medicinal products including ARO-AAT, JNJ-3989, ARO-APOC3, ARO-ANG3, ARO-ENaC, ARO-HIF2, ARO-Lung2, ARO-HSD, ARO-HIF2, AMG 890, ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3.The company develops pipeline drugs that are being developed to treat chronic hepatitis B infection for the treatment of liver disease, cardiovascular disease, hypertriglyceridemia, dyslipidemia, cystic fibrosis and and renal cell carcinoma. It also offers design of internal preclinical and clinical development programs to enable novel new...
-
Product Insights
NewNet Present Value Model: Arrowhead Pharmaceuticals Inc’s Plozasiran sodium
Empower your strategies with our Net Present Value Model: Arrowhead Pharmaceuticals Inc's Plozasiran sodium report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Arrowhead Pharmaceuticals Inc’s AROANG-3
Empower your strategies with our Net Present Value Model: Arrowhead Pharmaceuticals Inc's AROANG-3 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Arrowhead Pharmaceuticals Inc’s AROHIF-2
Empower your strategies with our Net Present Value Model: Arrowhead Pharmaceuticals Inc's AROHIF-2 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Arrowhead Pharmaceuticals Inc’s Fazirsiran sodium
Empower your strategies with our Net Present Value Model: Arrowhead Pharmaceuticals Inc's Fazirsiran sodium report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Arrowhead Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Arrowhead Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Clesrovimab
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Clesrovimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Thematic Analysis
NewRNA-Based Drugs and the Impact of COVID-19
This report investigates the past, current and future landscape of RNA-Based drugs, and how the success of the COVID-19 vaccines may have impacted this. High level analysis of the key trends and movements within the pharmaceutical industry in reference to RNA technology is provided, allowing you to identify and discern the key points within this area.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zodasiran in Mixed Dyslipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zodasiran in Mixed Dyslipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zodasiran in Mixed Dyslipidemia Drug Details: AROANG-3 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zodasiran in Homozygous Familial Hypercholesterolemia (HoFH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zodasiran in Homozygous Familial Hypercholesterolemia (HoFH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zodasiran in Homozygous Familial Hypercholesterolemia (HoFH) Drug Details: AROANG-3 is...